Peptides
Semaglutide's Cardiovascular Dividend: What the Latest Meta-Analyses Reveal
Two fresh syntheses sharpen the picture of how the most-talked-about GLP-1 protects the heart — and where the evidence still has gaps.
semaglutide
Peptides
The Next GLP-1s: Dual Fatty-Acid Conjugates and Combo Therapies Push Past Semaglutide
Two 2025 preclinical studies hint at where this class is heading — longer-acting molecules, beta-cell-protective stacks, and the first real challengers to semaglutide's throne.
Peptides
Why GLP-1 Drugs Last for Days: The Lipid Trick Behind Semaglutide's Half-Life
Native GLP-1 vanishes from your bloodstream in minutes. A fatty-acid tail turns it into a once-weekly shot — but the same trick that buys time also makes the drug harder to manufacture.
Peptides
The GLP-1 Side-Effect File: New Signals on Surgery, Pancreatitis, and the Gallbladder
Semaglutide and tirzepatide are reshaping body composition for millions of lifters and dieters. A cluster of 2025 reports is starting to map what happens when these drugs collide with surgery, scopes, and scans.
Metabolic Health
GLP-1s Without Diabetes: New Surgical Data Complicates the 'Weight-Loss Only' Story
A retrospective hip-replacement study suggests non-diabetic GLP-1 users may not face the malnutrition penalty surgeons feared — but the questions are bigger than one paper.
Metabolic Health
Beyond Weight Loss: What the Latest GLP-1 Evidence Says About Liver, Kidney, Heart, and Cost
Fresh 2025 reviews map semaglutide's reach into fatty liver disease, cardiovascular risk, kidney protection — and the economics of treating obesity at scale. The signals are real, but the picture is still filling in.
Metabolic Health
GLP-1s Grow Up: What the Latest Research Says About Weight Regain, Brain Health, and Your Eyes
A cluster of new 2025 papers reframes GLP-1 drugs as long-horizon metabolic tools — with real promise after bariatric surgery, a tantalizing brain-protection signal, and one safety question worth taking seriously.
Metabolic Health
Beyond Blood Sugar: How Semaglutide and Tirzepatide Are Rewriting Cardiometabolic Medicine
A new wave of 2025 research suggests GLP-1 and dual GIP/GLP-1 drugs do more than shrink waistlines and tame A1c — they may protect the heart at the cellular level, and hint at effects we are only beginning to map.
Metabolic Health
Beyond Weight Loss: Why GLP-1 Drugs Are Becoming Cardio-Metabolic Workhorses
Semaglutide and tirzepatide started as obesity treatments. A wave of moderate-quality evidence is pushing them toward something bigger — and asking new questions about inflammation, the heart, and even cancer.
Peptides
Semaglutide's Expanding Map: Beyond Weight Loss to Heart, Skin, and Fat Biology
A wave of 2025 research suggests GLP-1 agonists are doing more than shrinking waistlines — nudging lipid panels, reshaping fat tissue, and edging into cardiology and dermatology. The signal is real, but still moderate.